On October 5, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12th through 14th, 2021 (Press release, Scopus BioPharma, OCT 5, 2021, View Source [SID1234590807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting in-person on behalf of the company. Dr. Horsager’s presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11:00 AM Eastern Time / 8:00 AM Pacific Time at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website. Management will be available for one-on-one meetings to be held throughout the conference.

Investors interested in attending the conference in-person or virtually can register here. Once registered, you can request one-on-one meetings with the company through the conference website.

Dr. Horsager recently presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet’s unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

As previously announced, Scopus will also be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on Wednesday, October 6, 2021 at 5:00 PM Eastern Time. Investors interested in attending the virtual conference can register here.

About LD Micro Main Event

The 2021 LD Micro Main Event (XIV) will be held at the Luxe Sunset Bel-Air in Los Angeles from October 12th through 14th, 2021. The festivities run from 8:00 AM Pacific Time through 5:30 PM Pacific Time on October 12th and 13th with a morning session on October 14th. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in-person. For more information, please contact [email protected].

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

– RNA silencing CpG-STAT3siRNA ("DUET-01")
– Antisense CpG-STAT3ASO ("DUET-02")
– DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

On October 5, 2021 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, reported that it will host a Virtual R&D Day on 11 October 2021 at 1:00pm BST (8:00am EDT) (Press release, Redx Pharma, OCT 5, 2021, View Source [SID1234590806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day will include an update from the Company’s leadership team on Redx’s RXC004 programme and the potential of porcupine inhibition in Wnt-ligand driven colorectal, pancreatic and biliary cancers. There will also be an update on the Phase 1 study of RXC007, the Company’s selective ROCK2 inhibitor, being developed for idiopathic pulmonary fibrosis.

The programme includes presentations from leading experts:
· Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Presentation Title: ‘Potential of Porcupine Inhibition with RXC004 in Genetically Selected Patients with Metastatic MSS Colorectal Cancer’
· Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles Presentation Title: ‘Idiopathic Pulmonary Fibrosis’
· Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
Presentation Title: ‘The Importance of ROCK in Fibrosis’
To register for the webcast, please email [email protected]. A recording of the webcast will be available on Redx’s website after the event

On October 5, 2021 Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, reported the appointment of Olaf Christensen, M.D., as Chief Medical Officer (Press release, Orum Therapeutics, OCT 5, 2021, View Source [SID1234590805]). He will lead the clinical development of Orum’s first-in-class targeted protein degraders from the company’s Antibody neoDegrader Conjugate (AnDC) platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We welcome Olaf to the team at this important time for Orum as we transition into a clinical stage biotech," said Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics. "Olaf brings extensive experience in oncology drug development, and we look forward to his leadership in realizing our vision of translating innovative science into breakthrough medicines."

"I am excited to join the Orum Therapeutics team, which works at the cutting edge of targeted protein degradation therapy," said Dr. Christensen. "Orum’s AnDC platform has the potential to steer the power of protein degraders with the precision of ADC technology in multiple indications with high unmet clinical need for the benefit of cancer patients. We are at the beginning of an exciting journey to bring this new class of drugs to patients."

Dr. Christensen has more than 15 years of experience in oncology drug development as an executive leader overseeing phase 1 through phase 4 clinical projects. Most recently, he was Vice President, Head of Oncology Global Clinical Development at EMD Serono, the healthcare business of Merck KGaA in the U.S. and Canada, where he was responsible for development of early to late stage pipeline compounds including immuno-oncology and targeted therapies. Earlier in his career, he worked at Bayer Pharmaceuticals and subsequently in the immuno-oncology clinical development group at Bristol Myers Squibb. He received his M.D. degree at the Albertus Magnus University Cologne, Germany, completed a dissertation in immunotherapy, and trained in oncology at the Clinic for Hematology/Oncology at the University of Heidelberg, Germany.

On October 5, 2021 Almac Sciences, a member of the Almac Group, reported expanding collaborations with University College Dublin (UCD) for flow based-oxidation approaches through a co-founded PhD scholarship (Press release, Almac, OCT 5, 2021, View Source [SID1234590798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Almac Sciences and Dr Marcus Baumann have an already well-established partnership through a Science Foundation Ireland (SFI) Industry Fellowship on the Continuous Biocatalysed Chemicals (CATCH) project which was publicised in 2020. Together the team has published six peer-reviewed papers focusing on the development of continuous flow approaches to demonstrate the synergies between technology platforms, such as flow chemistry and biocatalysis. Highlights include development of Curtius rearrangements under flow and demonstration of the synergies attainable with biocatalysis with a novel enzyme mediated purification strategy.

The new PhD scholarship is co-funded by Almac Sciences and the SFI Research Centre for Pharmaceuticals (SSPC) over the next 4 years and will investigate flow-based oxidation processes. This year’s student, Niamh Disney, will undertake industry placements within Almac, offering an immersive experience on which she will build key transferable skills and gain insight into critical decision-making for flow processes on an industrial scale.

Lead academic at UCD, Dr Marcus Baumann said "I am very excited to continue to work with Almac Sciences and publish further as we investigate novel oxidative approaches under continuous flow. It affords further extension of my research portfolio in industrially relevant fields."

This latest development demonstrates further Almac’s commitment to technology innovation as it continues to expand service offerings for the pharmaceutical, biotechnology, life sciences and fine chemical sectors following a £325,000 investment, specifically in flow capabilities.

Dr Megan Smyth, Technical Leader, Almac Sciences commented: "This PhD further intensifies our collaboration with the Baumann group at UCD and we look forward to working with Marcus and Niamh. Through close collaboration, and time with us at our state-of-the-art facilities, Niamh will gain a valuable insight into industrially relevant target transformations and I wish her every success with her studies."

On October 4, 2022 SomaGenics presented its novel wound healing therapeutic based on the sshRNA RNAi technology to the NIH Innovation Conference (Press release, SomaGenics, OCT 4, 2021, https://www.somagenics.com/news/2022/4/15/somagenics-presents-at-the-nih-innovation-conference-and-the-life-science-summit-company-showcase [SID1234612316]). SomaGenics also presented to investors at the Life Sciences Summit, held November 9-10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of its NIH SBIR funding for the wound healing program, SomaGenics was subsidized by the NIH SEED program to present free of charge to these life sciences investor conferences and, with other such participants, received valuable coaching and feedback from the venture capital investment community.